New Launch8 Mar 2025, 12:08 am
Biocon Biologics' Yesintek™ Biosimilar to Ustekinumab Shows Equivalent Efficacy in Phase 3 Study for Chronic Plaque Psoriasis
AI Summary
Biocon Biologics, a fully integrated global biosimilars company, announced positive results from a pivotal Phase 3 study comparing its biosimilar Yesintek™ to the reference product Stelara (Ustekinumab) in adult patients with moderate to severe chronic plaque psoriasis. The study demonstrated equivalent efficacy, safety, immunogenicity, and pharmacokinetics between Yesintek™ and Stelara (Ustekinumab), marking a significant milestone for Biocon Biologics in advancing the accessibility of biosimilar therapies for patients worldwide.
Key Highlights
- Biocon Biologics' Yesintek™ biosimilar to Ustekinumab shows equivalent efficacy to reference product Stelara (Ustekinumab) in Phase 3 study for chronic plaque psoriasis.
- The study also demonstrated similar safety, immunogenicity, and pharmacokinetics profiles between Yesintek™ and Stelara (Ustekinumab).
- The positive results from this Phase 3 study reaffirm the quality and therapeutic equivalence of Yesintek™ compared to reference product Ustekinumab.
- Yesintek™ offers an effective, safe, and comparable alternative to reference Ustekinumab in the treatment of moderate to severe chronic plaque psoriasis and other indications.
- Biocon Biologics is committed to providing cost-effective, high-quality biosimilars to patients with chronic conditions like psoriasis, expanding access to critical treatments globally.